title: Hit and lead criteria in drug discovery for infectious diseases of the developing world.
abstract: Reducing the burden of infectious diseases that affect people in the developing world requires sustained collaborative drug discovery efforts. The quality of the chemical starting points for such projects is a key factor in improving the likelihood of clinical success, and so it is important to set clear go/no-go criteria for the progression of hit and lead compounds. With this in mind, the Japanese Global Health Innovative Technology (GHIT) Fund convened with experts from the Medicines for Malaria Venture, the Drugs for Neglected Diseases initiative and the TB Alliance, together with representatives from the Bill &Melinda Gates Foundation, to set disease-specific criteria for hits and leads for malaria, tuberculosis, visceral leishmaniasis and Chagas disease. Here, we present the agreed criteria and discuss the underlying rationale.
authors.affiliation: Global Health Innovative Technology (GHIT) Fund, Ark Hills, Sengokuyama Mori Tower (25F), 1-9-10 Roppongi, Minato-ku, Tokyo 106-0032, Japan.
authors.forename: Kei
authors.initials: K
authors.lastname: Katsuno
authors.affiliation: Medicines for Malaria Venture (MMV), 20, Route de Pré-Bois, 1215 Geneva 15, Switzerland.
authors.forename: Jeremy N
authors.initials: JN
authors.lastname: Burrows
authors.affiliation: Bill &Melinda Gates Foundation, PO Box 23350, Seattle, Washington 98102, USA.
authors.forename: Ken
authors.initials: K
authors.lastname: Duncan
authors.affiliation: Medicines for Malaria Venture (MMV), 20, Route de Pré-Bois, 1215 Geneva 15, Switzerland.
authors.forename: Rob
authors.initials: R
authors.lastname: Hooft van Huijsduijnen
authors.affiliation: Global Alliance for TB Drug Development (TB Alliance), 40 Wall Street, 24th Floor, New York, New York 10005, USA.
authors.forename: Takushi
authors.initials: T
authors.lastname: Kaneko
authors.affiliation: University of Tokyo, 7-3-1, Hongo, Bunkyo, Tokyo 113-0033, Japan.
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Kita
authors.affiliation: Drugs for Neglected Diseases initiative (DNDi), 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland.
authors.forename: Charles E
authors.initials: CE
authors.lastname: Mowbray
authors.affiliation: Medicines for Malaria Venture (MMV), 20, Route de Pré-Bois, 1215 Geneva 15, Switzerland.
authors.forename: Dennis
authors.initials: D
authors.lastname: Schmatz
authors.affiliation: Bill &Melinda Gates Foundation, PO Box 23350, Seattle, Washington 98102, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Warner
authors.affiliation: Global Health Innovative Technology (GHIT) Fund, Ark Hills, Sengokuyama Mori Tower (25F), 1-9-10 Roppongi, Minato-ku, Tokyo 106-0032, Japan.
authors.forename: B T
authors.initials: BT
authors.lastname: Slingsby
mesh_terms: D000818:Animals; D003141:Communicable Diseases / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology; D003906:Developing Countries / Q000191:economics; D055808:Drug Discovery / Q000191:economics / Q000639:trends*; D016568:Drugs, Generic / Q000191:economics / Q000627:therapeutic use; D005582:Foundations / Q000191:economics / Q000639:trends*; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D058069:Neglected Diseases / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D014376:Tuberculosis / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology
chemical_list: D016568:Drugs, Generic